When it comes to the affordability challenge, have payers and drugmakers reached a stalemate in the U.S.?
Pricing wars continue to rage, pharma initiatives are having lackluster impact, and payers are still not happy. At the same time, U.S. President Donald Trump is waxing lyrical about sweeping change which most of the industry expect will likely never come to fruition.
In this highly-charged environment, what steps can be taken to actually move market access forward? This report steps away from the rhetoric and delves into the practicalities of how progress can really be made.
Click here for more information and how you can buy this report.
